OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age

Med Pediatr Oncol. 2001 Jan;36(1):239-42. doi: 10.1002/1096-911X(20010101)36:1<239::AID-MPO1058>3.0.CO;2-G.

Abstract

Background: This paper reports the toxicity of OPEC/OJEC chemotherapy in stage 4 neuroblastoma patients over 1 year of age.

Procedure: Ninety-five patients with stage 4 neuroblastoma received alternating courses of OPEC/OJEC--vincristine 1.5 mg/m2 (O), cisplatin 80 mg/m2 (P), etoposide 200 mg/m2 (E), cyclophosphamide 600 mg/m2 (C), and carboplatin 500 mg/m2 (J), every 21 days if there was haematological recovery.

Results: Seventy out of ninety-five (74%) patients completed seven or more courses and were evaluable for toxicity. Of these 70 patients, 33% had more than three episodes of fever and sepsis, 35% required more than five blood or platelet transfusions, 36% had grade 2 or more gastrointestinal toxicity and 9% had neurotoxicity. There was a median reduction in GFR of 32 ml/min/1.73 m2 (-46 to 134) and there was one toxic death.

Conclusions: OPEC/OJEC is a well-tolerated therapy for stage 4 neuroblastoma over 1 year of age.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3-Iodobenzylguanidine
  • Abdominal Neoplasms / diagnostic imaging
  • Abdominal Neoplasms / drug therapy
  • Abdominal Neoplasms / mortality
  • Abdominal Neoplasms / pathology
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Marrow / pathology
  • Bone Marrow Diseases / chemically induced*
  • Bone Marrow Diseases / epidemiology
  • Bone Neoplasms / diagnostic imaging
  • Bone Neoplasms / secondary
  • Carboplatin / administration & dosage
  • Carboplatin / adverse effects
  • Child, Preschool
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Diphosphonates
  • Disease-Free Survival
  • Etoposide / administration & dosage
  • Etoposide / adverse effects
  • Female
  • Gastrointestinal Diseases / chemically induced*
  • Gastrointestinal Diseases / epidemiology
  • Humans
  • Incidence
  • Infant
  • Iodine Radioisotopes
  • Kidney Diseases / chemically induced*
  • Kidney Diseases / epidemiology
  • Male
  • Neoplasm Staging
  • Nervous System Diseases / chemically induced*
  • Nervous System Diseases / epidemiology
  • Neuroblastoma / diagnostic imaging
  • Neuroblastoma / drug therapy*
  • Neuroblastoma / mortality
  • Neuroblastoma / pathology
  • Neuroblastoma / secondary
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Remission Induction
  • Survival Analysis
  • Survival Rate
  • Technetium Compounds
  • Treatment Outcome
  • Vincristine / administration & dosage
  • Vincristine / adverse effects

Substances

  • Diphosphonates
  • Iodine Radioisotopes
  • Radiopharmaceuticals
  • Technetium Compounds
  • 3-Iodobenzylguanidine
  • Vincristine
  • Etoposide
  • Cyclophosphamide
  • technetium Tc 99m diphosphonate
  • Carboplatin
  • Cisplatin

Supplementary concepts

  • OPEC OJEC protocol